Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TAKE AWAY FAST FOOD JOINTS AND GOVT. SEND EVERYBODY TO WHOLE HEALTH FOOD STORES*****HUGE , HUGEEEE, VERY HUGEEE AS TRUMP WOULD SAY, WILL BE SAVED. THE SYSTEM MY FRIEND
4 sure, really cut it out
RSLS: Indeed!!! OBESITY --- as we all know & observe here every day in the USA --- is America's singularly BIGGEST National health threat.
4AM SHOULD BE FUN TO SEE
YEP!!! It's a $10-$20 stock, for sure.
CCCC IS UNSTOPPABLE, STILL GOING
ALONG WITH 25 DAYS NOTHING BY MOUTH
HIGHLIGHT YOUR MESSAGE, CLICK "B" ON THE LEFT HAND SIDE, HIGHLIGHT AGAIN AND CLICK "B".
hit .37 AH, I flipped and looking to reload b$ the close
wow your post with them super bold letters
how ya do that?
I'm right again, it appears. Technical synchronization came Friday. Now it is trying to spin in the toilet. After bell volume will likely get some ears up.
LAP BAND 2 OR LAP BAND 3?????????
THAT SEEMS THE TREND AT THIS PARTICULAR POINT IN TIME*****4AM IT SHALL BE***MIGHT RUN DOUBLE AND DROP BAGS ON 930AM TRADERS... OR MIGHT ANNOUNCE RS RIGHT AT THE GATE
ONE CAN NEVER TELL
i had bought .33's on the first dip , just rebought now afte the POP and drop
.33 is their last offering price, and we know how the 4AM+ crews likes to buy these low priced stocks with news
.33 should be a good buy, have bids in lower just in case
FLOAT SEEMS TO BE ******AND MOVEMENT NORTH SHOULD****
agree, BUT AS USUAL PLAY THE PLAY TRADE THE TREND
JUST OPINION,
WATCHING LIKE AN OWL
MIGHT NOT GO FAR, IT IS "SUPPLEMENTAL" AND RS MIGHT BE ON THE TABLE
$RSLS ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX
https://www.globenewswire.com/news-release/2023/12/12/2795114/0/en/ReShape-Lifesciences-Receives-FDA-PMA-Supplement-Approval-for-its-Next-Generation-Lap-Band-2-0-FLEX.html
Yep. This one should go a bit. eom
Where is the link to the offering ?
Just shorts getting chewed up and spit out onto the ground.
offering of 9,100,000 units, price of $0.33. The warrants will be immediately exercisable at a price of $0.33 per share, subject to reduction as set forth in the warrants, and will expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance.
Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $3.0 million. The offering is expected to close on October 3, 2023, subject to customary closing conditions.
Who knows 👈
$RSLS - ReShape Lifesciences, Inc.
— John Zidar (@JohnZidar) October 25, 2023
No apparently catalyst
👆 Up 44.3% After-Market/ Current Price $0.297
Wonder how many millions of naked short shares are at risk of getting squeezed when the news hits, will they end up covering over $0.40,or will it be higher, a large amount covering after hours,and buyers loading shares, someone must know something.
Thank you. HUGE VOLUMES
EXACTLY : BS PR
ANOTHER PUMP AND DUMP
PR not out and it's already running as of after hours yesterday. PR should be coming soon
I blinked and it's up 200%
And there you have it... a new $3M offering without even so much as a kiss!!!
RSLS: Hey, interesting NEWS spot there, Boss! OBESITY is (unfortunately) 'TRENDING' throughout the entire WESTERN HEMISPHERE!! And RSLS up a tiny pinch in the A.H., right now.
And yeah, the only thing poppin' today was that MEDS creature --- but, ya had to FLIP-IT in the after- and pre-markets, that's for sure. (Lastly, @WGS snuck-one-in just one minute after the Close today; nothing EPIC in their PR, per se, but a curious news spot.)
Hey! You didn't miss much today pretty dull. Yea man, you are stinking obese but hey you have great rhythm so that makes up for it. I like lol
RSLS: Monster THANKS, Capt. S-L, for the heads-up!!! (I was away all day today behind personal stuff!!) Hey, Boss, I myself want RSLS's Lap-Band-2.0 gadget!!! Heck, see MY joyous reaction, below, when I got your heads-up about it!!! Now ya know what a FAT PIG I am, Boss!!! I HATE when this happens to any of my fellow Human Beings, Homeboy --- let alone when it happens to my own stupid BIG FAT BUTT!!!
"I want that LAP-BAND-TWO-POINT-OH, two-point-oh, two-point-oh, BIG MAMA --- I said OH-OH-OH-OH, TWO=POINT-00000000000000000000000000, OH-YEAH --- BIG-BIG-BIG-BIG-BIG-BIG-FAT-&-GREASY-MAMA!!!!"
Followers
|
55
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2677
|
Created
|
10/23/17
|
Type
|
Free
|
Moderators |
ReShape Lifesciences™
https://www.reshapelifesciences.com/
ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved ReShape Balloon™ System involves a non-surgical weight loss procedure that uses advanced balloon technology designed to take up room in the stomach to help people with a 30-40 kg/m2 Body Mass Index (BMI) and at least one co-morbidity lose weight. ReShape vBloc™ Therapy, delivered by an FDA-approved pacemaker-like device called the ReShape vBloc System, is designed to help patients with a 40-45 kg/m2, or a 35-39.9 kg/m2 BMI and at least one co-morbidity feel full and eat less by intermittently blocking hunger signals on the vagus nerve. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.
ReShape Lifesciences was incorporated in Minnesota in December 2002 under the name Beta Medical, Inc. In 2003, the Company changed its name to EnteroMedics Inc. and in 2004 reincorporated in Delaware. EnteroMedics began trading on the NASDAQ Stock Market on November 15, 2007. The Company acquired ReShape Medical, Inc. in October 2017 and subsequently changed its name to ReShape Lifesciences, Inc.
Financials http://ir.reshapelifesciences.com/static-files/cefa86e6-3998-4cb2-b8d8-c5447d7383b5
PART I – FINANCIAL INFORMATION ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS RESHAPE LIFESCIENCES INC. Condensed Consolidated Balance Sheets (Unaudited) June 30, December 31, 2018 2017 ASSETS Current assets: Cash and cash equivalents $ 1,863,217 $ 10,163,208 Accounts receivable (net of allowance for bad debts of $228,165 and $155,872 at June 30, 2018 and December 31, 2017) 446,027 488,613 Inventory 2,101,017 2,817,112 Prepaid expenses and other current assets 919,543 467,783 Total current assets 5,329,804 13,936,716 Property and equipment, net 303,206 438,621 Goodwill — 27,186,620 Other intangible assets, net 44,802,230 46,152,577 Other assets 76,827 990,015 Total assets $ 50,512,067 $ 88,704,549 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 4,201,239 $ 1,088,271 Accrued expenses 4,499,875 5,955,518 Total current liabilities 8,701,114 7,043,789 Deferred income taxes 2,700,681 5,292,291 Common stock warrant liability 74 1,600 Total liabilities 11,401,869 12,337,680 Commitments and contingencies (Note 7) Stockholders’ equity: Preferred stock, 5,000,000 shares authorized: Series B convertible preferred stock, $0.01 par value; 20,000 shares issued and 2,957 and 6,055 shares outstanding at June 30, 2018 and December 31, 2017, respectively 30 61 Series C convertible preferred stock, $0.01 par value; 187,772 shares issued and 95,388 shares outstanding at June 30, 2018 and December 31, 2017 954 954 Series D convertible preferred stock, $0.01 par value; 6,000 shares issued and 4,750 and zero shares outstanding at June 30, 2018 and December 31, 2017 48 — Common stock, $0.01 par value; 275,000,000 shares authorized at June 30, 2018 and December 31, 2017; 3,610,009 and 2,063,808 shares issued and outstanding at June 30, 2018 and December 31, 2017 36,100 20,640 Additional paid-in capital 424,158,496 411,104,568 Accumulated deficit (385,085,430) (334,759,354) Total stockholders’ equity 39,110,198 76,366,869 Total liabilities and stockholders’ equity $ 50,512,067 $ 88,704,549 See accompanying notes to condensed consolidated financial statements.
RESHAPE LIFESCIENCES INC. Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Product sales $ 633,554 $ 93,060 $ 1,574,985 $ 133,100 Other revenue 19,815 — 28,382 — Total revenue 653,369 93,060 1,603,367 133,100 Cost of revenue 634,774 54,472 1,463,731 83,995 Gross profit 18,595 38,588 139,636 49,105 Operating expenses: Selling, general and administrative 6,710,518 5,560,787 16,756,075 11,489,773 Research and development 2,439,337 1,352,075 5,126,856 2,476,488 Goodwill impairment 27,186,620 — 27,186,620 — Total operating expenses 36,336,475 6,912,862 49,069,551 13,966,261 Operating loss (36,317,880) (6,874,274) (48,929,915) (13,917,156) Other income (expense): Interest income 263 — 674 100 Interest expense — — (2,735) — Change in value of warrant liability 369 34,395 1,494 (288,735) Other, net (142,145) (298) (144,416) (1,198) Loss before income taxes (36,459,393) (6,840,177) (49,074,898) (14,206,989) Income tax benefit 1,208,560 — 2,590,613 — Net loss $ (35,250,833) $ (6,840,177) $ (46,484,285) $ (14,206,989) Adjustment for convertible preferred stock and warrants (3,841,790) — (3,841,790) — Net loss attributable to common shareholders (39,092,623) (6,840,177) (50,326,075) (14,206,989) Net loss per share—basic and diluted $ (15.78) $ (13.68) $ (22.14) $ (32.13) Shares used to compute basic and diluted net loss per share 2,477,910 500,114 2,273,160 442,191
The Company trades on the NASDAQ under the ticker symbol RSLS.http://ir.reshapelifesciences.com/financial-information/sec-filings
As of August 10, 2018, 9,013,421 shares of the registrant’s Common Stock were outstanding.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |